Abstract
Background and Aim Perioperative blood transfusion is associated with increased morbidity and mortality. Acute normovolemic hemodilution (ANH) is a blood conservation strategy associated with variable success, and rarely studied in more complex cardiac procedures. The study aim was to evaluate whether acute ANH improves coagulopathy and reduces blood transfusions in thoracic aortic surgeries.
Methods Single-center observational cohort study comparing ANH and standard institutional practice in patients who underwent thoracic aortic repair from 2019 to 2021.
Results 89 patients underwent ANH and 116 standard practice. There were no significant differences between the groups in terms of demographic or major perioperative characteristics. In the ANH group coagulation tests before and after transfusion of autologous blood showed decreased INR and increased platelets, fibrinogen, all with p<0.0005. Coagulation results in the ANH and control groups were not statistically different. The average number of transfused allogeneic products per patient was lower in the ANH vs control group: FFP 1.1 ±1.6 vs 1.9 ±2.3 (p=0.003), platelets 0.6 ±0.8 vs 1.2 ±1.3 (p=0.0008), and cryoprecipitate 0.3 ±0.7 vs 0.7 ±1.1 (p=0.008). Reduction in RBC transfusion was not statistically significant. The percentage of patients who received any transfusion was 53.9% in ANH and 59.5% in the control group (p=0.42). There was no significant difference in major adverse outcomes.
Conclusions ANH is a safe blood conservation strategy for surgical repairs of the thoracic aorta. Laboratory data suggests that ANH can improve coagulopathy after separation from CPB, and significantly reduce the number of transfused FFP, platelets and cryoprecipitate.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of Alabama at Birmingham Institutional Review Board (Project Number: IRB-300005436; Approval Date: 06/12/2019).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interests: The authors have no conflicts of interests to disclose.
Funding: No funding was received for the study.
Ethics Statement: The study was approved and informed consent waived by the University of Alabama at Birmingham Institutional Review Board (Project Number: IRB-300005436; Approval Date: 06/12/2019).
Data Availability
The data that support the findings of this study are available on request from the corresponding author (dmladinov@uabmc.edu).
Abbreviations
- ANH
- acute normovolemic hemodilution
- AWB
- autologous whole blood
- CPB
- cardiopulmonary bypass
- ECMO
- extracorporeal membrane oxygenation
- FFP
- fresh frozen plasma
- INR
- international normalized ratio
- PT
- Prothrombin time
- PTT
- Partial thromboplastin time
- RBC(s)
- red blood cell(s)
- TEE
- transesophageal echocardiography